Miscellaneous hematological agents:

Indications for: ANGIOMAX

Anticoagulation with concomitant aspirin in: unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA); patients with, or at risk of, heparin–induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS) undergoing percutaneous coronary intervention (PCI), and in patients undergoing PCI with provisional use of glycoprotein IIb/IIIa (GPI).

Adult Dosage:

Give with aspirin 300–325mg daily: initiate 0.75mg/kg IV bolus (may give additional bolus of 0.3mg/kg after 5mins, if needed in those without HIT/HITTS), followed by 1.75mg/kg/hr for duration of procedure. May continue infusion up to 4hrs post-procedure; after 4hrs, may give additional infusion of 0.2mg/kg/hr up to 20hrs, if needed. Renal impairment: CrCl <30mL/min: reduce infusion rate to 1mg/kg/hr; hemodialysis: 0.25mg/kg/hr.

Children Dosage:

Not established.

ANGIOMAX Contraindications:

Active major bleeding.

ANGIOMAX Warnings/Precautions:

Consider stopping if symptoms of bleeding occur. Increased risk of thrombus formation with brachytherapy. Diseases associated with an increased bleeding risk. Monitor for acute stent thrombosis and signs/symptoms of MI in STEMI patients following PCI. Renal impairment. Pregnancy. Nursing mothers.

ANGIOMAX Classification:


ANGIOMAX Interactions:

Increased bleeding risk with warfarin, heparin, thrombolytics. Interferes with INR measurements.

Adverse Reactions:


Generic Drug Availability:


How Supplied:

Single-use vial—1